Graham Capital Management L.P. bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,201 shares of the medical research company's stock, valued at approximately $2,201,000.
A number of other large investors have also recently added to or reduced their stakes in the company. Howard Capital Management Inc. raised its stake in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after purchasing an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the last quarter. Cypress Wealth Services LLC raised its holdings in shares of IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after purchasing an additional 57 shares during the period. Harbor Investment Advisory LLC lifted its stake in IQVIA by 4.7% in the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the last quarter. Finally, Magnolia Capital Advisors LLC lifted its stake in IQVIA by 2.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after purchasing an additional 74 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Trading Down 0.9%
Shares of IQVIA stock traded down $1.31 on Thursday, hitting $140.51. 2,595,876 shares of the company's stock traded hands, compared to its average volume of 1,504,221. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a fifty day moving average of $161.62 and a two-hundred day moving average of $187.11. The company has a market capitalization of $24.31 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the company earned $2.54 EPS. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. JPMorgan Chase & Co. dropped their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Barclays cut their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $230.76.
View Our Latest Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
